Scholarlink

<p>We conducted a phenotypic screen of 20,000 central nervous system (CNS)-biased small molecules for their ability to stimulate differentiation of mouse oligodendrocyte progenitor cells (OPCs) into oligodendrocytes. We identified a lead hit (CN045) with an EC<sub>50</sub> of 40 nM in the OPC differentiation assay and a chemical scaffold conducive to modifications. In OPC differentiation assays, CN045 demonstrated higher potency than a known OPC differentiation compound Triiodothyronine (T3). CN045 promoted myelin-like ensheathment of engineered nanofibers by mouse and human OPCs and significantly increased remyelination in white and gray matter regions of mouse brain following cuprizone/rapamycin-induced demyelination. In terms of pharmacokinetics, CN045 is CNS-penetrable with low cytotoxicity. CN045 has a short half-life in vivo, but its chemical scaffold is conducive to structural modifications that can improve its metabolic properties. Collectively, these results demonstrate that CN045 is an attractive lead candidate for enhancing OPC differentiation and remyelination in multiple sclerosis patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A novel small molecule remyelination therapy for multiple sclerosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月23日

查看全文
  • Yan Yang,
  • Brain Bai,
  • Lars J. S. Knutsen,
  • Richard J. Hamlyn,
  • Qiao-Ling Cui,
  • Jack Antel,
  • Wendy Macklin,
  • Satish Medicetty,
  • Bruce D. Trapp

摘要

We conducted a phenotypic screen of 20,000 central nervous system (CNS)-biased small molecules for their ability to stimulate differentiation of mouse oligodendrocyte progenitor cells (OPCs) into oligodendrocytes. We identified a lead hit (CN045) with an EC50 of 40 nM in the OPC differentiation assay and a chemical scaffold conducive to modifications. In OPC differentiation assays, CN045 demonstrated higher potency than a known OPC differentiation compound Triiodothyronine (T3). CN045 promoted myelin-like ensheathment of engineered nanofibers by mouse and human OPCs and significantly increased remyelination in white and gray matter regions of mouse brain following cuprizone/rapamycin-induced demyelination. In terms of pharmacokinetics, CN045 is CNS-penetrable with low cytotoxicity. CN045 has a short half-life in vivo, but its chemical scaffold is conducive to structural modifications that can improve its metabolic properties. Collectively, these results demonstrate that CN045 is an attractive lead candidate for enhancing OPC differentiation and remyelination in multiple sclerosis patients.